Marfan Syndrome

Written by Nabil Ebraheim

Questions and Answers for Reading, Listening, and Clinical Recall. An experiment in medical education.

Q: What is the molecular defect in Marfan syndrome? A: Pathogenic variants in the FBN1 gene on chromosome 15, encoding fibrillin‑1, a key component of microfibrils in connective tissue.​​

Q: A 12-year-old girl is tall and slender with arachnodactyly, pectus carinatum, joint laxity, scoliosis, and ectopia lentis. What is the most likely cause of her condition? A: An autosomal-dominant mutation of the FBN1 gene on chromosome 15 encoding fibrillin-1, leading to Marfan syndrome.

Q: What is the inheritance pattern of Marfan syndrome? A: Autosomal dominant.​​

Q: A man with Marfan syndrome has an unaffected wife. What is the likelihood that their children will be affected? A: 50% of the sons and 50% of the daughters.

Q: An asymptomatic patient has a 30° scoliotic curve, normal neurologic exam, and an increased metacarpal index on hand radiograph. What should be recommended? A: Cardiac consultation, including an echocardiogram.

Q: The overexpression of which factor is responsible for dilation of the aorta in patients with mutations in the fibrillin gene? A: Transforming growth factor beta (TGF-β).

Q: Marfan syndrome is associated with scoliosis and dural ectasia. What is dural ectasia, why does it occur in Marfan syndrome, and how is it detected? A: Dural ectasia is an abnormal widening and weakening of the dural sac surrounding the spinal cord, especially in the lumbosacral spine, caused by defective connective tissue due to an FBN1 mutation. It is a major systemic feature in the Ghent criteria and strongly supports the diagnosis of Marfan syndrome. It occurs because weak fibrillin-1 leads to reduced structural support of the dura and increased TGF-β activity, allowing the dura to stretch under normal cerebrospinal fluid pressure. It is detected by MRI.

Q: What are the characteristic skeletal features of Marfan syndrome? A: Tall stature with increased arm span, arachnodactyly, joint laxity, pectus excavatum or carinatum, scoliosis, and acetabular or hip protrusio.​​

Q: What are the classic physical exam signs for Marfan skeletal features? A: The thumb sign (Steinberg sign) and the wrist sign (Walker–Murdoch sign). Thumb (Steinberg) sign: The patient makes a fist with the thumb tucked inside the palm. If the thumb tip sticks out past the edge of the hand, the sign is positive. This shows abnormally long fingers. Wrist (Walker–Murdoch) sign: The patient wraps the thumb and little finger around the opposite wrist. If the thumb and little finger overlap, the sign is positive. This shows long, slender fingers and limbs. Why these signs matter: They reflect arachnodactyly (spider-like fingers), a classic skeletal feature of Marfan syndrome, caused by abnormal connective tissue leading to long bones and joint laxity.

Q: How does Marfan syndrome affect the cardiovascular system, and what is the molecular biology problem? A: Marfan syndrome is caused by mutations in the FBN1 gene, which encodes fibrillin-1, a key structural protein of elastic fibers in the aortic wall. Defective fibrillin-1 weakens elastic tissue and fails to properly sequester TGF-β, leading to excess TGF-β signaling. This results in degeneration of the aortic media, loss of elastic recoil, and progressive aortic root dilation, predisposing to aortic regurgitation, dissection, and rupture.

Q: What ocular finding is characteristic of Marfan syndrome? A: Ectopia lentis with superior and temporal lens subluxation in many patients.​​

Q: How does fibrillin‑1 deficiency lead to aortic disease in Marfan syndrome? A: Abnormal microfibrils weaken the aortic media and dysregulate TGF‑β signaling, predisposing to progressive dilation and dissection.​​

TGF-β and Fibrillin-1

Q: What is TGF-β? A: TGF-β (transforming growth factor-beta) is a signaling protein that controls cell behavior and tissue remodeling, especially extracellular matrix production and repair. Q: What does TGF-β normally do in the aorta? A: It helps regulate how the aortic wall is built and maintained by directing vascular smooth muscle cells and controlling extracellular matrix remodeling. Q: What is fibrillin-1, and where is it found? A: Fibrillin-1 is a structural protein that forms extracellular microfibrils; it is found in the connective tissue matrix, especially in the aorta (elastic fibers of the aortic media), ligaments, skin, lung, and the zonular fibers that suspend the lens. Q: Where does fibrillin-1 come from, and where does it go? A: It is produced by fibroblasts and vascular smooth muscle cells, secreted outside the cell, and assembled into microfibrils in the extracellular matrix. Q: How does fibrillin-1 normally affect TGF-β? A: Microfibrils bind and store TGF-β in an inactive form in the extracellular matrix, limiting excess signaling. Q: What happens in Marfan syndrome? A: Mutations in FBN1 lead to abnormal fibrillin-1, causing weak microfibrils and reduced sequestration of TGF-β. Q: Why does this lead to aortic root dilation and dissection? A: The aortic wall becomes mechanically weaker and is exposed to excessive TGF-β signaling, driving abnormal remodeling and progressive dilation that increases risk of dissection.

Normally, fibrillin-1 made by connective tissue cells is assembled into microfibrils in the extracellular matrix of the aortic wall, where it supports elastic fibers and helps keep TGF-β stored in an inactive state so remodeling stays balanced. When fibrillin-1 is defective in Marfan syndrome (FBN1 mutation), microfibrils and elastic fiber support are weakened and TGF-β is no longer well sequestered, so signaling becomes excessive and the aortic wall remodels abnormally, leading to progressive aortic root dilation and increased risk of dissection.

What is FBN1? FBNI is the gene that encodes fibrillin-1, a structural protein of the extracellular matrix that forms microfibrils (a scaffold for elastic fibers) and helps regulate TGF-β signaling. Mutations in FBN1 cause Marfan syndrome. FBN1 encodes fibrillin-1 means the FBN1 gene is the DNA recipe that cells read to build the fibrillin-1 protein.

Q: What orthopedic issues commonly arise in Marfan patients? A: Progressive scoliosis, chest wall deformity, joint laxity with pain or instability, and protrusio acetabuli or hip dysplasia.​​

Q: How is Marfan syndrome diagnosed clinically? A: By the revised Ghent criteria, which integrate FBN1 mutation status, aortic root dimensions, ocular findings, and systemic skeletal features.​

Q: What is the main strategy to reduce aortic complications in Marfan syndrome? A: Strict blood pressure control, often with beta‑blockers or angiotensin receptor blockers, and prophylactic aortic root surgery at defined size thresholds.​​

Q: How does Marfan differ from homocystinuria in lens position and joints? A: Marfan typically has superior lens dislocation and joint laxity, whereas homocystinuria usually has inferior lens dislocation and joint stiffness.​​

Q: What dental or craniofacial features may be seen in Marfan syndrome? A: High‑arched palate, crowding of teeth, and sometimes retrognathia.​

Q: Why should contact and high‑impact sports be restricted in Marfan patients? A: To reduce risk of aortic dissection or rupture, lens dislocation, and joint injury.​

Q: What is the typical intellect in Marfan syndrome? A: Most patients have normal intelligence.​

Q: What obstetric consideration is important for women with Marfan syndrome? A: Pregnancy increases hemodynamic stress on the aorta, requiring close cardiology monitoring and sometimes pre‑pregnancy aortic surgery.​

Q: What role does imaging play in Marfan follow‑up? A: Regular echocardiography or cross‑sectional imaging to monitor aortic root size and detect progression toward surgical thresholds.​

Q: Which bones are often involved in protrusio associated with Marfan syndrome? A: The acetabulum and proximal femur, with medial migration of the femoral head.​

Q: How can Marfan‑related scoliosis influence orthopedic management? A: It may progress rapidly in adolescence and sometimes requires bracing or surgical fusion, with careful attention to cardiopulmonary status.​

Q: What is the systemic score concept in Marfan diagnosis? A: A point system assigning weight to skeletal, ocular, skin, and pulmonary features to quantify systemic involvement.​

Q: Why is early recognition of Marfan syndrome critical for prognosis? A: Timely cardiovascular surveillance and intervention dramatically reduce mortality from aortic dissection or rupture.​​

• Marfan syndrome is an autosomal dominant fibrillin‑1 disorder with prominent cardiovascular, ocular, and skeletal manifestations.​​
• Tall stature, joint laxity, chest wall deformity, and hip protrusio coexist with superior lens ectopia and progressive aortic root dilation that can culminate in dissection.​​

Marfan syndrome arises from FBN1 mutations that impair fibrillin‑1 microfibrils and alter TGF‑β signaling in the aortic wall, ligaments, and zonular fibers of the eye. Clinically, patients present with striking skeletal features including tall, thin habitus, arachnodactyly, pectus deformity, scoliosis, and protrusio acetabuli, along with superior lens subluxation and risk of aortic root aneurysm and dissection. Modern management combines genetic diagnosis, regular imaging of the aorta, pharmacologic afterload reduction, and timely prophylactic aortic surgery, substantially improving survival when combined with orthopedic care for skeletal deformities.

Comparison table: Marfan vs homocystinuria